<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Endocrinol Metab</journal-id><journal-id journal-id-type="publisher-id">IJEM</journal-id><journal-title-group><journal-title>Indian Journal of Endocrinology and Metabolism</journal-title></journal-title-group><issn pub-type="ppub">2230-8210</issn><issn pub-type="epub">2230-9500</issn><publisher><publisher-name>Medknow Publications &#x00026; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23226666</article-id><article-id pub-id-type="pmc">3510940</article-id><article-id pub-id-type="publisher-id">IJEM-16-1048a</article-id><article-id pub-id-type="doi">10.4103/2230-8210.103040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letters to the Editor</subject></subj-group></article-categories><title-group><article-title>Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus&#x02019;</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mundra</surname><given-names>Vishal</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><italic>Department of Internal Medicine, St. John Medical Center, Tulsa, USA</italic></aff><author-notes><corresp id="cor1"><bold>Corresponding Author:</bold> Dr. Vishal Mundra, SJP Hospitalist, 1705 E. 19<sup>th</sup> St., Holliman Building, Suite 302, Tulsa, OK 74104,, USA. E-mail: <email xlink:href="mundravishal@hotmail.com">mundravishal@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Nov-Dec</season><year>2012</year></pub-date><volume>16</volume><issue>6</issue><fpage seq="a">1048</fpage><lpage>1048</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Endocrinology and Metabolism</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions></article-meta></front><body><p>Sir,</p><p>This letter is in response to the interesting study published by Ved and Shah titled &#x02013; &#x02018;Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over three months in patients with type 2 diabetes mellitus&#x02019;.</p><p>Incretin based therapy are the new effective innovation in the treatment of diabetes. We thank Dr. Paresh Ved and Dr. Samrat Shah for sharing the finding of this multicenter study with us but this study raised a few questions which were left unanswered. First of all, how many patients received vildagliptin vs FDC combination of vildagliptin and metformin? Secondly, how was the dose titrated upwards for them? Did the clinician follow a protocol across all the centers? Was there a significant difference in HbA1c drop/FPG/PPG change in all the three groups? Also, they reported weight loss as one of the benefit of using DPP-IV inhibitors. In a recent meta-analysis[<xref ref-type="bibr" rid="ref1">1</xref>] and a randomized trial[<xref ref-type="bibr" rid="ref2">2</xref>] they have been found to be weight neutral. If the weight change associated with concurrent metformin use, was not clarified in the study. Lastly, there were no comments on the adverse events seen in each group separately.</p><p>As the authors mentioned, elderly patient may be better candidate for such therapy as they have lower risk of hypoglycemia.[<xref ref-type="bibr" rid="ref3">3</xref>] However, they also tend to have higher incidence of renal dysfunction which requires very careful selection. This study supports the findings that both drugs execute complimentary actions achieving better glycemic control.[<xref ref-type="bibr" rid="ref4">4</xref><xref ref-type="bibr" rid="ref5">5</xref>] Recently FDA also approved use of exenatide in combination with long acting insulin based on a study published by Buse <italic>et al</italic>.[<xref ref-type="bibr" rid="ref6">6</xref>]</p><p>We definitely need more randomized trials to further elucidate the role of DPP-IV inhibitors and their benefit in terms of cardiac, lipids and insulin sensitivity as mentioned by the authors.</p></body><back><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amori</surname><given-names>RE</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name><name><surname>Pittas</surname><given-names>AG</given-names></name></person-group><article-title>Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis</article-title><source>JAMA</source><year>2007</year><volume>298</volume><fpage>194</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">17622601</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>BJ</given-names></name><name><surname>Feinglos</surname><given-names>MN</given-names></name><name><surname>Lunceford</surname><given-names>JK</given-names></name><name><surname>Johnson</surname><given-names>J</given-names></name><name><surname>Williams-Herman</surname><given-names>DE</given-names></name></person-group><collab>Sitagliptin 036 Study Group</collab><article-title>Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>1979</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">17485570</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>SL</given-names></name></person-group><article-title>Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors</article-title><source>Am J Geriatr Pharmacother</source><year>2010</year><volume>8</volume><fpage>405</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">21335294</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group><article-title>DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials</article-title><source>Diabetes Metab</source><year>2012</year><volume>38</volume><fpage>89</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">22197148</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheen</surname><given-names>AJ</given-names></name></person-group><article-title>Metformin + saxagliptin for type 2 diabetes</article-title><source>Expert Opin Pharmacother</source><year>2012</year><volume>13</volume><fpage>139</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">22149373</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Glass</surname><given-names>LC</given-names></name><name><surname>Heilmann</surname><given-names>CR</given-names></name><name><surname>Lewis</surname><given-names>MS</given-names></name><name><surname>Kwan</surname><given-names>AY</given-names></name><etal/></person-group><article-title>Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial</article-title><source>Ann Intern Med</source><year>2011</year><volume>154</volume><fpage>103</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">21138825</pub-id></element-citation></ref></ref-list></back></article>